There are currently 2875 clinical trials in Houston, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including M D Anderson Cancer Center, University of Texas MD Anderson Cancer Center, Baylor College of Medicine and The University of Texas - MD Anderson Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma
NCT05039281
Recruiting
This phase I/II trial tests the safety and side effects of atezolizumab in combination with cabozantinib and whether they work to shrink tumors in patients with glioblastoma that has come back (recurrent). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giv... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Recurrent Glioblastoma, Recurrent Gliosarcoma
Register for Updates
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
NCT04947254
Recruiting
This phase II trial studies the effect of androgen ablation therapy with or without niraparib after standard of care radiation therapy in treating patients with prostate cancer that has not spread to other parts of the body (localized) or that has spread to nearby tissue or lymph nodes (locally advanced). Androgen ablation therapy (also known as hormone therapy) lowers the levels of male hormones called androgens in the body. Androgens stimulate prostate cancer cells to grow. There are 2 types o... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Prostate Carcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Register for Updates
Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma
NCT04199026
Recruiting
This early phase I trial studies the side effects of implanting and removing a microdevice in patients with sarcomas that have spread to other places in the body (metastatic) or have come back (recurrent). Microdevices are rice-sized devices that are implanted into tumor tissue and are loaded with 10 different drugs that are delivered at very small doses, or "microdoses," which may only affect a very small, local area inside the tumor. The purpose of this study is to determine which drugs delive... Read More
Gender:
ALL
Ages:
10 years and above
Trial Updated:
08/13/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Metastatic Sarcoma, Recurrent Sarcoma, Resectable Sarcoma
Register for Updates
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
NCT04743141
Recruiting
The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of migraine in children and adolescents (≥ 6 to \< 18 years of age).
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
08/13/2025
Locations: Trio Clinical Trials, LLC., Houston, Texas +3 locations
Conditions: Acute Treatment of Migraine
Register for Updates
Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
NCT04278768
Recruiting
This is a multicenter, open-label, Phase 1/2a dose escalation and expansion study of orally administered emavusertib (CA-4948) monotherapy in adult patients with AML or higher- risk Myelodysplastic Syndrome (hrMDS). Patients enrolling in the Phase 1 dose escalation of the study must meet one of the following criteria prior to consenting to the study: * Relapse/refractory (R/R) AML with FMS-like tyrosine kinase-3 (FLT3) mutations who have been previously treated with a FLT3 inhibitor * R/R AML... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Register for Updates
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
NCT04649242
Recruiting
The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in children and adolescents.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
08/13/2025
Locations: UTHealth Houston, Houston, Texas +4 locations
Conditions: Pediatric Migraine
Register for Updates
A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
NCT04570423
Recruiting
The purpose of this study is to evaluate the safety and pharmacokinetics of eflapegrastim in pediatric participants with solid tumors or lymphoma and treated with myelosuppressive chemotherapy.
Gender:
ALL
Ages:
Between 1 month and 17 years
Trial Updated:
08/13/2025
Locations: UT MD Anderson Cancer Center, Houston, Texas
Conditions: Solid Tumors, Lymphoma
Register for Updates
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
NCT01810913
Recruiting
This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squamous cell). Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin and docetaxel, wor... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: M D Anderson Cancer Center, Houston, Texas +1 locations
Conditions: Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7, Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma
Register for Updates
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459
Recruiting
This study will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection fraction (HFpEF) and HF with mildly reduced ejection fraction (HFmrEF) who are obese. This is a phase 3, global, multicenter, 2-part study with a double-blind period and an open-label extension (OLE). The... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
08/13/2025
Locations: East Texas Cardiology PA, Houston, Texas +2 locations
Conditions: Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
Register for Updates
Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature
NCT04674969
Recruiting
The ELEGANCE Registry's objective is to collect Real-World Data (RWD), including populations previously not represented in Peripheral Vascular Disease (PVD) trials, health economics data, and to support the safe use of commercially available Boston Scientific Corporation (BSC) drug-eluting devices for the treatment of lesions located in the peripheral vasculature.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: Baylor College of Medicine, Houston, Texas
Conditions: Peripheral Vascular Diseases
Register for Updates
Clinicopathologic and Ancillary Testing of Primary Clear Cell Carcinoma of the Cervix
NCT05046080
Recruiting
This study aims to provide a comprehensive report on clinicopathologic features, immunohistochemical/biomarker testing and molecular profile of cervical clear cell carcinoma. This study may help researchers learn more about the molecular profile of cervical clear cell carcinoma.
Gender:
FEMALE
Ages:
All
Trial Updated:
08/13/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type
Register for Updates
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
NCT07037433
Recruiting
The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.
Gender:
ALL
Ages:
Between 45 years and 99 years
Trial Updated:
08/13/2025
Locations: Biopharma Informatic, LLC, Houston, Texas +2 locations
Conditions: Atherosclerotic Cardiovascular Disease, Overweight, Obesity
Register for Updates